By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Lysosomal enzymes > Naglazyme
Lysosomal enzymes

Naglazyme

https://themeditary.com/drug/naglazyme-2425.html
Medically Reviewed by Philip Thornton, DipPharm TheMediTary.Com | Reviewed: Jul 13, 2023  Additional Content by TheMediTary.Com

Generic name: galsulfase [ gal-sul-fase ]

Drug class: Lysosomal enzymes

Dosage form: intravenous infusion

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Brand names: Galsulfase

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Naglazyme?

Naglazyme contains an enzyme that occurs naturally in the body in healthy people. Some people lack this enzyme because of a genetic disorder. Galsulfase helps replace this missing enzyme in such people.

Naglazyme is used to treat some of the symptoms of a genetic condition called mucopolysaccharidosis VI (MYOO-koe-pol-ee-SAK-a-rye-DOE-sis type 6), or MPS VI, also called Maroteaux-Lamy syndrome.

MPS VI is a metabolic disorder in which the body lacks the enzyme needed to break down certain natural substances. These substances can build up in the body, causing enlarged organs, abnormal bone structure, changes in facial features, breathing problems, heart problems, vision or hearing loss, and changes in mental or physical abilities.

Naglazyme may improve walking and stair-climbing ability in people with this condition. However, this medication is not a cure for MPS VI.

Warnings

An allergic reaction may occur during or shortly after the Naglazyme infusion. Tell your caregivers or get emergency medical help right away if you have any signs of a severe allergic reaction, such as chest pain, trouble breathing, vomiting, skin rash or redness, and feeling like you might pass out.

Before taking this medicine

Your Naglazyme infusion may be delayed if you have a fever or cold symptoms.

To make sure Naglazyme is safe for you, tell your doctor if you have ever had:

  • breathing problems; or

  • sleep apnea, and you use a continuous positive airway pressure (CPAP) machine.

Tell your doctor if you are pregnant or breastfeeding.

Your name may need to be listed on an MPS IV Registry while you are using Naglazyme. The purpose of this registry is to track the progression of this disorder and the effects that galsulfase has on long-term treatment of MPS IV. The registry also tracks the effects of galsulfase on a baby if you are pregnant or breastfeeding.

Naglazyme pregnancy and breastfeeding warnings (more detail)

How should I take Naglazyme

Naglazyme is given as an infusion into a vein. A healthcare provider will give you this injection.

Naglazyme is usually given once per week.

Tell your doctor if you have been sick with a fever or cold. You may need to wait until you get better before receiving your dose of Naglazyme.

Naglazyme must be given slowly, and the infusion can take up to 4 hours to complete.

About 30 to 60 minutes before each injection, you will be given other medications to help prevent a serious allergic reaction.

Your doctor will need to check your progress on a regular basis.

Dosing information

Usual Adult Dose for Mucopolysaccharidosis Type VI:

1 mg/kg IV once a week

Comments:
-Clinical studies did not include patients older than 29 years and it is therefore unknown if they respond differently than younger patients.

Use: For the treatment of patients with Mucopolysaccharidosis VI (MPS VI [Maroteaux-Lamy syndrome])

Usual Pediatric Dose for Mucopolysaccharidosis Type VI:

5 years or older: 1 mg/kg IV once a week

Use: For the treatment of patients with MPS VI (Maroteaux-Lamy syndrome)

Detailed Naglazyme dosage information
Naglazyme Dosage information (more detail)

Before Taking

Your Naglazyme infusion may be delayed if you have a fever or cold symptoms.

To make sure Naglazyme is safe for you, tell your doctor if you have ever had:

  • breathing problems; or

  • sleep apnea, and you use a continuous positive airway pressure (CPAP) machine.

Tell your doctor if you are pregnant or breastfeeding.

Your name may need to be listed on an MPS IV Registry while you are using Naglazyme. The purpose of this registry is to track the progression of this disorder and the effects that galsulfase has on long-term treatment of MPS IV. The registry also tracks the effects of galsulfase on a baby if you are pregnant or breastfeeding.

Naglazyme pregnancy and breastfeeding warnings (more detail)

Related/similar drugs

galsulfase

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your Naglazyme injection.

What happens if I overdose?

Since this medication is given by a healthcare professional in a medical setting, an overdose is unlikely to occur.

What should I avoid while using Naglazyme?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

Naglazyme side effects

Get emergency medical help if you have signs of an allergic reaction to Naglazyme: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

An allergic reaction may occur during or shortly after infusion of this medicine (up to 24 hours later). Tell your caregivers or get emergency medical help right away if you have any signs of a severe allergic reaction, such as:

  • rapid breathing, or feeling short of breath;

  • chest pain;

  • feeling like you might pass out, even while lying down;

  • fever, chills;

  • skin rash or redness, itching;

  • eye redness;

  • headache; or

  • vomiting, stomach pain.

Even though it may not be a side effect of galsulfase, increased pressure on the spinal cord is a complication of MPS VI that may occur while you are using Naglazyme. Tell your doctor right away if you have any symptoms of spinal cord compression: back pain, loss of movement in any part of your body, loss of bowel or bladder control.

Call your doctor at once if you have:

  • snoring or sleep apnea, trouble breathing;

  • swelling, rapid weight gain; or

  • shortness of breath (even with mild exertion).

Common Naglazyme side effects may include:

  • fever, chills;

  • trouble breathing;

  • pain;

  • rash or itching;

  • headache; or

  • nausea, vomiting, stomach pain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

See more: Naglazyme Side Effects

More about Naglazyme (Galsulfase [ gal-sul-fase ])

Dosage information
Naglazyme Side Effects
During pregnancy
Naglazyme Prescribing Information
Drug images
Side effects
Drug class: Lysosomal enzymes

Related treatment guides

Mucopolysaccharidosis Type VI
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by